Avenue Therapeutics Valuation Multiples

Avenue Therapeutics is valued at $988K as of November 2026. In the last fiscal year, Avenue Therapeutics revenue was $1M and Avenue Therapeutics EBITDA was ($3M).

Avenue Therapeutics Overview

About Avenue Therapeutics

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its current product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's Disease), intravenous tramadol (IV tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders.


Founded

2015

HQ

United States

Employees

2

Financials (Last FY)

Revenue: $1M
EBITDA: ($3M)

Market Cap

$988K

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Avenue Therapeutics Financials

Avenue Therapeutics reported last fiscal year revenue of $1M and negative EBITDA of ($3M).

In the same fiscal year, Avenue Therapeutics generated ($3M) in EBITDA losses and had net loss of ($3M).


Avenue Therapeutics P&L

In the most recent fiscal year, Avenue Therapeutics reported revenue of $1M and EBITDA of ($3M).

Avenue Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (219%) and net margin of (207%).

See analyst estimates for Avenue Therapeutics
Last FY2025202620272028
Revenue$1M$1M
EBITDA($3M)($3M)
EBITDA Margin(219%)(219%)
EBIT Margin(234%)(234%)
Net Profit($3M)($3M)
Net Margin(207%)(207%)

Financial data powered by Morningstar, Inc.

Avenue Therapeutics Stock Performance

Avenue Therapeutics has current market cap of $988K.

Market Cap Evolution


Avenue Therapeutics' stock price is $0.30.

Avenue Therapeutics has an EPS (earnings per share) of $-0.88.

See more trading valuation data for Avenue Therapeutics
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$988K7.1%---$-0.88

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Avenue Therapeutics Valuation Multiples

Avenue Therapeutics Financial Valuation Multiples

As of November 19, 2026, Avenue Therapeutics has market cap of $988K.

Avenue Therapeutics has a P/E ratio of (0.3x).

Last FY2025202620272028
P/E(0.3x)(0.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Avenue Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Avenue Therapeutics Margins & Growth Rates

In the most recent fiscal year, Avenue Therapeutics reported EBITDA margin of (219%) and net margin of (207%).

See estimated margins and future growth rates for Avenue Therapeutics

Avenue Therapeutics Margins

Last FY2025202720282029
EBITDA Margin(219%)(219%)
EBIT Margin(234%)(234%)
Net Margin(207%)(207%)
FCF Margin(131%)(131%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Avenue Therapeutics Operational KPIs

Avenue Therapeutics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $2.2M for the same period.

Access forward-looking KPIs for Avenue Therapeutics
Last FY2025202620272028
Revenue per Employee$0.7M-
Opex per Employee$2.2M-
G&A Expenses to Revenue260%260%
R&D Expenses to Revenue74%74%
Opex to Revenue320%320%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Avenue Therapeutics Competitors

Avenue Therapeutics competitors include Bone Biologics, Matinas BioPharma Holdings, Cannovum Cannabis, Silexion Therapeutics, Biodexa Pharmaceuticals, Geovax Labs, Gabather, Respiratorius, RAMM Pharma and Karyopharm Therapeutics.

Most Avenue Therapeutics public comparables operate across Biopharmaceuticals and BioTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Bone Biologics-($3M)----
Matinas BioPharma Holdings-($10M)--(0.0x)-
Cannovum Cannabis-($447K)--(2.1x)-
Silexion Therapeutics-($12M)----
Biodexa Pharmaceuticals-($8M)----
Geovax Labs$2M($22M)----
Gabather-($446K)--(1.7x)(1.6x)
Respiratorius-($350K)--(3.2x)-

This data is available for Pro users. Sign up to see all Avenue Therapeutics competitors and their valuation data.

Start Free Trial

Avenue Therapeutics VC Funding History

Before going public, Avenue Therapeutics raised $35M in total equity funding, across 1 round.

Last private valuation of Avenue Therapeutics was $105M, after raising $35M in November 2018 from Cipla.


Avenue Therapeutics Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Nov-18Strategic investmentCipla$35M$105MInvaGen Pharmaceuticals, the US subsidiary of Indian drugmaker Cipla, agreed in November 2018 to acquire Avenue Therapeutics in two stages. In the first stage InvaGen would subscribe to newly issued shares representing 33.3% of Avenue's capital stock on a fully diluted basis for USD 35 million, at USD 6.00 a share, and appoint three directors. In the second stage it would buy the remaining shares for up to USD 180 million in aggregate, expected to be about USD 13.92 a share, through a reverse subsidiary merger, subject to US FDA approval of IV Tramadol, its labelling and scheduling and the absence of risk-evaluation restrictions. The headline value was about USD 215 million. The first stage closed on 8 February 2019, when InvaGen acquired 5,833,333 shares. Cipla chief executive Umang Vohra said the transaction established the group's presence in the specialty institutional business in the US. Avenue Therapeutics is a specialty pharmaceutical company, controlled by Fortress Biotech, focused on developing and commercialising intravenous tramadol for acute pain, and its shares trade on Nasdaq.

Acquisitions by Avenue Therapeutics

Avenue Therapeutics has acquired 1 company to date.

Last acquisition by Avenue Therapeutics was on November 8th 2022. Avenue Therapeutics acquired Baergic Bio for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Avenue Therapeutics

Baergic Bio
Description
Baergic Bio is a clinical-stage biopharmaceutical company based in New York that develops BAER-101, an oral GABA-A alpha 2/3 receptor modulator licensed from AstraZeneca for central nervous system disorders. Avenue Therapeutics acquired it from Fortress Biotech in 2022.
HQ CountryUnited States
HQ City
New York City, NY
Deal Date8 Nov 2022
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Avenue Therapeutics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Avenue Therapeutics

When was Avenue Therapeutics founded?Avenue Therapeutics was founded in 2015.
Where is Avenue Therapeutics headquartered?Avenue Therapeutics is headquartered in United States.
How many employees does Avenue Therapeutics have?As of today, Avenue Therapeutics has over 2 employees.
Is Avenue Therapeutics publicly listed?Yes, Avenue Therapeutics is a public company listed on OTCM.
What is the stock symbol of Avenue Therapeutics?Avenue Therapeutics trades under ATXI ticker.
When did Avenue Therapeutics go public?Avenue Therapeutics went public in 2017.
Who are competitors of Avenue Therapeutics?Avenue Therapeutics main competitors include Bone Biologics, Matinas BioPharma Holdings, Cannovum Cannabis, Silexion Therapeutics, Biodexa Pharmaceuticals, Geovax Labs, Gabather, Respiratorius, RAMM Pharma, Karyopharm Therapeutics.
What is the current market cap of Avenue Therapeutics?Avenue Therapeutics' current market cap is $988K.
What is the current revenue of Avenue Therapeutics?Avenue Therapeutics' last fiscal year revenue is $1M.
Is Avenue Therapeutics profitable?No, Avenue Therapeutics is not profitable.
How many companies Avenue Therapeutics has acquired to date?As of November 2026, Avenue Therapeutics has acquired 1 company.
What was the largest acquisition by Avenue Therapeutics?None of the M&A deals Avenue Therapeutics has completed have disclosed valuations.
What companies Avenue Therapeutics acquired?Avenue Therapeutics acquired Baergic Bio.
In how many companies Avenue Therapeutics has invested to date?Avenue Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Avenue Therapeutics

Lists including Avenue Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial